What types of colorectal cancer overexpress the MAGE protein?

Hepatogastroenterology. 2004 Nov-Dec;51(60):1648-52.

Abstract

Background/aims: Tumor-specific antigens such as Melanoma-associated antigens could be attractive targets for immunotherapy. It will be a great help for cancer immunotherapy to distinguish what types of tumor expresses tumor-specific antigen.

Methodology: We investigated the expression pattern of MAGE-A1 by immunohistochemical typing methods in human colorectal cancers obtained from consecutive patients undergoing surgical treatment at the hospital of the University of Tokyo.

Results: In 35 of 89 cases (39%), MAGE-A1 positive immunoreactivity was detected in the malignant glands. MAGE-A1 positive immunoreactivity was significantly higher among the patients under the age of 70 than among those 70 years of age and older (p=0.04). Among the patients under the age of 70, the tumors located in the distal colon (descending colon, sigmoid colon and rectum) showed significantly more positive MAGE-A1 immunoreactivity than those in the proximal colon (cecum, ascending colon and transverse colon) (p=0.04). The expression pattern of MAGE-A1 was not associated with gender, size, depth, histological type, vessel invasion, lymphatic invasion, lymph nodal invasion or stage of disease.

Conclusions: Relatively better results can be expected with MAGE-A1 immunotherapy among patients with distal colon cancer under the age of 70.

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antigens, Neoplasm
  • Biomarkers, Tumor / analysis
  • Biopsy, Needle
  • Cohort Studies
  • Colorectal Neoplasms / immunology*
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / therapy*
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunohistochemistry
  • Immunotherapy / methods*
  • Male
  • Melanoma-Specific Antigens
  • Middle Aged
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / immunology*
  • Neoplasm Proteins / metabolism*
  • Neoplasm Staging
  • Probability
  • Prognosis
  • Risk Assessment
  • Sensitivity and Specificity

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Melanoma-Specific Antigens
  • Neoplasm Proteins